XmAb®27564

· Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb®27564, covering 2025-12-02 to 2025-12-02. Get the full timeline:

Most recent: Clinical Trial Update: Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis [Phase 1]